Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1434)	9/26/2002 8:26:27 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

Very simple..... I've asked them..... how can a molecule be both a glutathione derivative and a product of TRAP? I never got an answer. Then there was the 100% (now ninety something) success rate for TRAP, with a large number of partners, but none of the "successes" were of sufficient quality to trigger a milestone. The GNSC project was a success, but it seems to be a success of the same nature as all those other successes. The 286 mechanism seemed to have been r(d)efined a bit late in the game. 199 also targets GST. Two key scientists are no longer there. OTOH, there seems to be a ton of enthusiasm from the physicians running the trial, and I saw some impressive "before and after" MRIs from the UCLA phase I trial.